Paradigm Financial Partners LLC Acquires 158 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Paradigm Financial Partners LLC boosted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.7% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,688 shares of the medical research company’s stock after buying an additional 158 shares during the quarter. Thermo Fisher Scientific makes up 1.2% of Paradigm Financial Partners LLC’s holdings, making the stock its 18th biggest holding. Paradigm Financial Partners LLC’s holdings in Thermo Fisher Scientific were worth $5,142,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. International Assets Investment Management LLC lifted its stake in Thermo Fisher Scientific by 61,995.4% in the 4th quarter. International Assets Investment Management LLC now owns 1,009,671 shares of the medical research company’s stock valued at $535,923,000 after purchasing an additional 1,008,045 shares during the last quarter. Loomis Sayles & Co. L P boosted its holdings in shares of Thermo Fisher Scientific by 17,046.7% during the 3rd quarter. Loomis Sayles & Co. L P now owns 973,591 shares of the medical research company’s stock valued at $492,803,000 after acquiring an additional 967,913 shares in the last quarter. Rathbones Group PLC grew its position in Thermo Fisher Scientific by 111.0% during the 3rd quarter. Rathbones Group PLC now owns 568,970 shares of the medical research company’s stock worth $287,996,000 after acquiring an additional 299,338 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its position in Thermo Fisher Scientific by 20.3% in the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 1,706,179 shares of the medical research company’s stock valued at $863,617,000 after purchasing an additional 287,446 shares during the last quarter. Finally, Wellington Management Group LLP grew its holdings in shares of Thermo Fisher Scientific by 9.8% during the third quarter. Wellington Management Group LLP now owns 3,080,687 shares of the medical research company’s stock worth $1,559,351,000 after purchasing an additional 274,464 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total value of $5,556,300.00. Following the sale, the chief executive officer now owns 49,155 shares of the company’s stock, valued at $27,311,992.65. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, SVP Michael A. Boxer sold 14,566 shares of the business’s stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the sale, the senior vice president now directly owns 12,901 shares in the company, valued at approximately $7,250,362. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total transaction of $5,556,300.00. Following the completion of the sale, the chief executive officer now directly owns 49,155 shares in the company, valued at approximately $27,311,992.65. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 50,277 shares of company stock valued at $28,513,384. 0.32% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several research firms recently commented on TMO. Raymond James lifted their target price on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a research report on Thursday, February 1st. Citigroup began coverage on Thermo Fisher Scientific in a report on Monday, March 18th. They issued a “neutral” rating and a $620.00 price objective for the company. Barclays lifted their price objective on Thermo Fisher Scientific from $590.00 to $615.00 and gave the stock an “equal weight” rating in a research note on Thursday. Deutsche Bank Aktiengesellschaft raised their price target on shares of Thermo Fisher Scientific from $600.00 to $610.00 and gave the stock a “buy” rating in a report on Thursday. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Thermo Fisher Scientific in a research note on Monday, January 8th. Five analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $606.76.

Thermo Fisher Scientific Stock Up 0.3 %

Shares of NYSE TMO traded up $1.87 during trading on Friday, hitting $573.60. The stock had a trading volume of 1,438,184 shares, compared to its average volume of 1,317,052. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.70 and a quick ratio of 1.39. The firm has a fifty day moving average of $573.60 and a two-hundred day moving average of $530.14. Thermo Fisher Scientific Inc. has a 12 month low of $415.60 and a 12 month high of $603.82. The company has a market capitalization of $218.95 billion, a PE ratio of 36.79, a PEG ratio of 2.42 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, April 24th. The medical research company reported $5.11 EPS for the quarter, topping the consensus estimate of $4.70 by $0.41. The firm had revenue of $10.35 billion for the quarter, compared to analysts’ expectations of $10.14 billion. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. As a group, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 21.56 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were given a dividend of $0.39 per share. The ex-dividend date of this dividend was Thursday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 annualized dividend and a dividend yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.01%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.